A yolk-shell nanocarrier was engineered to co-deliver doxorubicin and paclitaxel from separate compartments for rapid and sustained release. In A549 cells, comparable or greater cytotoxicity was reported at substantially lower loaded drug amounts. Evidence remains in vitro, without animal or human safety, distribution or efficacy data.
Key findings
- Rhodamine B release extended to 14 days, while methylene blue showed a 24-hour burst. Blank carriers showed no major toxicity in the assays, and A549 cytotoxicity was comparable or greater at approximately 15-fold lower doxorubicin and 10-fold lower paclitaxel effective loadings.
Why this matters globally
Timed multidrug delivery is a major nanomedicine challenge, and this platform offers a materials strategy for controlling exposure sequence.
Thai researcher contribution
Chiang Mai University researchers integrated nanomaterials, release engineering and cell biology in an anticancer delivery prototype.
Limitations to consider
Cell-culture cytotoxicity is not treatment efficacy. Pharmacokinetics, tumour distribution, clearance, immunotoxicity, stability, manufacturability and organ safety are unknown. Dose-loading comparisons require the full methods.